14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 19, 2026
VIVS vs SLS: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 19, 2026, SELLAS Life Sciences Group, Inc. (SLS) captures the overall head-to-head institutional edge over VivoSim Labs, Inc. (VIVS) on higher Unified Composite conviction (40.2/100 SELL vs. 39.0/100 SELL) after splitting the core matrix 5–2 (led by Profitability & Quality, Options & Positioning), while VIVS wins 3–2 across the 6-pillar growth and valuation breakdown. VIVS trades at $0.29 (N/M Forward P/E, -10117.0% operating margin) versus SLS at $14.86 (N/M Forward P/E, 0.0% operating margin).
Growth vs. Quality Trade-Off: SLS earns the overall head-to-head edge with a stronger Unified Composite Score (40.2/100 SELL vs. VIVS 39.0/100 SELL) and 1.84β · 551% Vol risk profile, whereas VIVS leads top-line expansion (-51.4% YoY revenue growth, N/M PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates.
Defensive Composite Rating Caution: Although SLS compares more favorably head-to-head, both VIVS (39.0/100 SELL) and SLS (40.2/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.
Technical & Structure Timing Caution: VIVS is currently in a Breakdown options structure phase (RSI 75.1); meanwhile SLS trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 60.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Competes within the Biotechnology value chain with $3.7B market capitalization and 0.0% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ VIVS vs SLS Key Questions & Quantitative Answers
As of Nov 19, 2026, SELLAS Life Sciences Group, Inc. (SLS) captures the overall head-to-head institutional edge over VivoSim Labs, Inc. (VIVS) on higher Unified Composite conviction (40.2/100 SELL vs. 39.0/100 SELL) after splitting the core matrix 5–2 (led by Profitability & Quality, Options & Positioning), while VIVS wins 3–2 across the 6-pillar growth and valuation breakdown. VIVS trades at $0.29 (N/M Forward P/E, -10117.0% operating margin) versus SLS at $14.86 (N/M Forward P/E, 0.0% operating margin). Growth vs. Quality Trade-Off: SLS earns the overall head-to-head edge with a stronger Unified Composite Score (40.2/100 SELL vs. VIVS 39.0/100 SELL) and 1.84β · 551% Vol risk profile, whereas VIVS leads top-line expansion (-51.4% YoY revenue growth, N/M PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates. Defensive Composite Rating Caution: Although SLS compares more favorably head-to-head, both VIVS (39.0/100 SELL) and SLS (40.2/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model. Technical & Structure Timing Caution: VIVS is currently in a Breakdown options structure phase (RSI 75.1); meanwhile SLS trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 60.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
VIVS leads the Growth & Scale pillar: VIVS posts -51.4% YoY revenue growth and +0.0% YoY earnings growth on $112,000 TTM revenue (N/A gross margin, -10117.0% operating margin), compared with SLS at -82.5% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). Across the 8-period historical trajectory (FY2019 to FY2026), VIVS cumulative revenue shifted N/A while SLS shifted N/A. In operating R&D and SG&A reinvestment, VIVS deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for SLS.
VIVS screens cheaper on headline valuation multiples. VIVS trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 9.6x EV/Revenue (unreported EBITDA margin), whereas SLS trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against VIVS (-343.1% ROE) versus SLS (-40.3% ROE) capital efficiency.
In options market volatility and institutional positioning, VIVS carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, ACCUMULATION on-balance volume, and sits in a BREAKDOWN options structure phase (0.83β · 480% Vol realized risk). By comparison, SLS carries 176.3% implied volatility (16th %ile, Compressed (<25th %ile)), a 0.43x (Call-Skewed) Put/Call open-interest ratio, ACCUMULATION on-balance volume, and sits in a CONSOLIDATION options structure phase (1.84β · 551% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 19, 2026. For educational research only; not investment advice.